Novartis’s tislelizumab phase-III trial data shows survival results in esophageal cancer
First-line tislelizumab plus chemotherapy showed median Overall Survival (OS) of 17.2 months versus 10.6 months for chemotherapy…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.